Shanghai RAAS Blood Products Co., Ltd. (SHE:002252)
China · Delayed Price · Currency is CNY 5.78
-0.07 (-1.20%)
Mar 30, 2026, 9:49 AM CST
SHE:002252 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 7,340 | 8,174 | 7,962 | 6,566 | 4,285 |
Other Revenue | 8.43 | 2.85 | 1.57 | 1.32 | 3.01 |
| 7,348 | 8,176 | 7,964 | 6,567 | 4,288 | |
Revenue Growth (YoY) | -10.13% | 2.67% | 21.27% | 53.16% | 55.26% |
Cost of Revenue | 4,658 | 4,872 | 4,735 | 3,678 | 2,069 |
Gross Profit | 2,690 | 3,304 | 3,229 | 2,889 | 2,219 |
Selling, General & Admin | 803.9 | 867.79 | 712.75 | 706.48 | 616.64 |
Research & Development | 223.37 | 250.9 | 173.74 | 145.71 | 129.02 |
Other Operating Expenses | 46.54 | 48.66 | 31.49 | 32.81 | 23.05 |
Operating Expenses | 1,094 | 1,211 | 912.68 | 900.18 | 756.75 |
Operating Income | 1,596 | 2,093 | 2,316 | 1,989 | 1,462 |
Interest Expense | -44.11 | -0.22 | -0.12 | -0.26 | -0.47 |
Interest & Investment Income | 422.59 | 634.16 | 135.38 | 510.69 | 466.09 |
Currency Exchange Gain (Loss) | 16.79 | -85.01 | -43.34 | -56.55 | 11.28 |
Other Non Operating Income (Expenses) | -11.27 | -0.08 | -0.42 | -1.42 | -1.91 |
EBT Excluding Unusual Items | 1,980 | 2,642 | 2,408 | 2,441 | 1,937 |
Impairment of Goodwill | -94.02 | - | - | -197.02 | -361.19 |
Gain (Loss) on Sale of Investments | - | - | -196.89 | 18.38 | -42.76 |
Gain (Loss) on Sale of Assets | 21.16 | -1.61 | -0.01 | 0.23 | -1.35 |
Asset Writedown | 0.07 | -13.23 | -4.31 | -2.47 | -9.26 |
Other Unusual Items | -1.73 | -7.07 | -2.52 | 13.11 | 16.54 |
Pretax Income | 1,906 | 2,620 | 2,204 | 2,274 | 1,539 |
Income Tax Expense | 328.93 | 426.31 | 426.65 | 400.61 | 250.09 |
Earnings From Continuing Operations | 1,577 | 2,194 | 1,777 | 1,873 | 1,289 |
Minority Interest in Earnings | 0.42 | -0.5 | 2.04 | 7.09 | 5.56 |
Net Income | 1,577 | 2,193 | 1,779 | 1,880 | 1,295 |
Net Income to Common | 1,577 | 2,193 | 1,779 | 1,880 | 1,295 |
Net Income Growth | -28.10% | 23.25% | -5.35% | 45.24% | -2.21% |
Shares Outstanding (Basic) | 6,578 | 6,617 | 6,591 | 6,741 | 6,741 |
Shares Outstanding (Diluted) | 6,583 | 6,617 | 6,591 | 6,741 | 6,741 |
Shares Change (YoY) | -0.51% | 0.39% | -2.23% | - | 5.28% |
EPS (Basic) | 0.24 | 0.33 | 0.27 | 0.28 | 0.19 |
EPS (Diluted) | 0.24 | 0.33 | 0.27 | 0.28 | 0.19 |
EPS Growth | -27.35% | 22.22% | -3.19% | 46.80% | -8.09% |
Free Cash Flow | -713.52 | -889.2 | 1,827 | 1,500 | 1,089 |
Free Cash Flow Per Share | -0.11 | -0.13 | 0.28 | 0.22 | 0.16 |
Dividend Per Share | 0.048 | 0.070 | 0.030 | 0.030 | 0.028 |
Dividend Growth | -31.00% | 133.33% | - | 7.14% | 12.00% |
Gross Margin | 36.61% | 40.41% | 40.54% | 43.99% | 51.75% |
Operating Margin | 21.72% | 25.60% | 29.09% | 30.29% | 34.10% |
Profit Margin | 21.46% | 26.82% | 22.34% | 28.63% | 30.19% |
Free Cash Flow Margin | -9.71% | -10.88% | 22.94% | 22.84% | 25.41% |
EBITDA | 1,818 | 2,299 | 2,477 | 2,169 | 1,616 |
EBITDA Margin | 24.74% | 28.11% | 31.10% | 33.03% | 37.69% |
D&A For EBITDA | 221.71 | 205.52 | 160.39 | 180.33 | 154.07 |
EBIT | 1,596 | 2,093 | 2,316 | 1,989 | 1,462 |
EBIT Margin | 21.72% | 25.60% | 29.09% | 30.29% | 34.10% |
Effective Tax Rate | 17.26% | 16.27% | 19.36% | 17.62% | 16.25% |
Revenue as Reported | - | - | 7,964 | 6,567 | 4,288 |
Advertising Expenses | 108.83 | 193.47 | 143.4 | 193.23 | 169.52 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.